XML 24 R4.htm IDEA: XBRL DOCUMENT v3.21.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Income Statement [Abstract]    
Net Revenues $ 15,586,976 $ 11,766,763
Cost of goods sold 1,616,625 1,209,300
Gross profit 13,970,351 10,557,463
Operating Expenses:    
Selling, general and administrative expense 18,683,594 13,067,569
Depreciation and amortization 291,370 119,951
Bad debt expense 30,000 110,000
Total operating expenses 19,004,964 13,297,520
Operating loss (5,034,613) (2,740,057)
Other Income/(Expense):    
Other income 14,822 10,198
Interest expense (11,528) (105,919)
Debt forgiveness 586,174 0
Total other income / (expense) 589,468 (95,721)
Net loss (4,445,145) (2,835,778)
Less: net loss attributable to noncontrolling interest (88,705) (21,690)
Net loss attributable to Sanara MedTech common shareholders $ (4,356,440) $ (2,814,088)
Basic loss per share of common stock $ (0.76) $ (1.32)
Diluted loss per share of common Stock $ (0.76) $ (1.32)
Weighted average number of common shares outstanding basic 5,734,537 2,132,745
Weighted average number of common shares outstanding diluted 5,734,537 2,132,745